Welcome to our dedicated page for Amesite news (Ticker: AMST), a resource for investors and traders seeking the latest updates and insights on Amesite stock.
Amesite Inc. reports developments tied to its AI-native healthcare software business, centered on the NurseMagic platform and EMR for non-acute and post-acute care. Company updates cover product expansion, documentation and workflow tools, HIPAA-related connectivity, electronic visit verification interfaces, enterprise adoption, and customer-facing updates for home health, hospice, skilled nursing, senior living, and home care settings.
News about AMST also includes capital-structure actions such as registered direct offerings, private placements, warrants, registration-statement activity, and Nasdaq listing compliance matters. These items frame the company’s financing, governance, and public-company status alongside its healthcare AI platform strategy.
Amesite Inc. (Nasdaq: AMST), an AI technology company, announces its participation in The Microcap Conference 2025 at the Borgata Hotel Spa & Casino in Atlantic City from January 28-30, 2025. CEO Dr. Ann Marie Sastry will deliver a corporate presentation on January 29 at 2:30 PM ET and conduct one-on-one meetings with investors.
The presentation will focus on recent developments of the company's NurseMagic™ app, an AI-powered mobile application designed for nursing professionals and home health care workers. The app aims to streamline daily tasks, enhance efficiency, improve patient communication, and support career development. Dr. Sastry will also discuss the company's growth strategy and monetization plans in both B2C and B2B markets.
Amesite Inc. (Nasdaq: AMST) has announced the closing of its 'best efforts' underwritten public offering, raising approximately $3.6 million through the sale of 1,201,667 shares of common stock at $3.00 per share. Company officers and directors participated in the offering with subscriptions totaling about $1.26 million.
The offering was jointly managed by Laidlaw & Company (UK) and Craft Capital Management The company plans to utilize the net proceeds for general corporate purposes, capital expenditures, working capital, and general and administrative expenses. The offering was conducted under a previously filed and effective shelf registration statement on Form S-3.
Amesite (Nasdaq: AMST) has announced the pricing of its 'best efforts' underwritten public offering of 1,201,667 shares of common stock at $3.00 per share, aiming to raise approximately $3.6 million. Company officers and directors are participating with subscriptions of about $1.26 million.
The offering is expected to close on January 8, 2025, with Laidlaw & Company and Craft Capital Management acting as joint book-running managers. The net proceeds will be used for general corporate purposes, capital expenditures, working capital, and general and administrative expenses.
The offering is being made pursuant to a shelf registration statement on Form S-3 that was declared effective by the SEC on December 18, 2024.
Amesite Inc (Nasdaq: AMST), an AI technology company focusing on B2C and B2B solutions, has announced plans for a 'best efforts' underwritten public offering of common stock and pre-funded warrants. Laidlaw & Company and Craft Capital Management will serve as joint book-running managers for the offering.
The offering will be conducted under a previously filed and effective shelf registration statement (Form S-3, Registration No. 333-282999) from December 18, 2024. The company plans to use the proceeds for general corporate purposes, capital expenditures, working capital, and administrative expenses.
The final terms, size, and completion of the offering remain subject to market conditions, with no guarantees of completion. A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC.
Amesite Inc. (NASDAQ: AMST) announced its participation in the Sidoti January Virtual Investor Conference on January 22-23, 2025, where CEO Dr. Ann Marie Sastry and VP of Sales Brandon Owens will present the company's success with NurseMagic™. The presentation is scheduled for January 22 at 10:45am ET.
NurseMagic™, the company's AI-driven healthcare solution, has achieved significant market penetration since its recent launch, now serving users across 87 different healthcare professions in all 50 US states and 21 countries. The platform supports various healthcare professionals, from registered nurses to healthcare CEOs, and has secured enterprise sales with major home care franchise companies. The solution includes both consumer subscriptions and a HIPAA-compliant enterprise offering.
Amesite Inc. (NASDAQ: AMST) announced the release of an end-of-year video shareholder update scheduled for December 23, 2024, at 3:00 pm ET. The presentation, led by CEO Dr. Ann Marie Sastry, will be accessible on the company's investor relations website. The update will cover key aspects of their NurseMagic™ product, including B2C and B2B offerings, revenue growth, marketing strategies, onboarding processes, and projected profitability metrics. Additionally, the presentation will address the company's infrastructure, user scaling capabilities, and financial position.
Amesite (NASDAQ: AMST) reports significant marketing growth for its NurseMagic™ AI-powered healthcare app. In the past 90 days, the company's social channels achieved remarkable engagement metrics, including 12.7 million account reaches, 550,000 likes, and 400,000 shares. The app, which provides real-time AI support for caregivers, has built a community of 32,000 engaged followers.
Within five months of public launch, NurseMagic™ has secured enterprise contracts with franchise owners, launched paid individual subscriptions, and achieved HIPAA compliance. The company is executing a dual B2B and B2C strategy, supported by testimonials from owners and influencer messaging to drive adoption.
Amesite Inc. (NASDAQ: AMST) has secured contracts with franchise owners of national brands for its NurseMagic™ app in the home health and home care industries. The contracts represent a significant milestone, demonstrating the app's scalability across hundreds of locations. NurseMagic™ addresses workforce performance challenges in an industry projected to grow from $100 billion in 2024 to $176 billion by 2032.
Multiple franchise owners, including those from Senior Helpers and BrightStar Care, have praised the platform's ease of use and effectiveness. The company's strategy involves offering accessible pricing with sustainable margins to drive widespread adoption. In just five months since launch, Amesite has achieved key milestones including paid individual subscriptions, HIPAA compliance, and revenue generation in the home care market.
Amesite (NASDAQ: AMST) announced that its AI-powered app NurseMagic™ is now available for direct consumer subscriptions, following its successful enterprise launch. The app has experienced strong user growth, supporting professionals from 87 professions across 50 states and 21 countries. NurseMagic™ assists healthcare professionals with various tasks including documentation, patient communication, and technical support.
The app has built a community of over 32,000 followers across social media channels and now meets HIPAA regulatory requirements. The company is marketing the enterprise version to major U.S. home health and home care businesses, positioning NurseMagic™ to generate revenue from both enterprise and consumer sales.
Amesite (NASDAQ: AMST) announced that its NurseMagic™ app now meets HIPAA requirements, targeting the $330 billion home health and home care industries. The AI-powered platform, launched six months ago, is currently used by over 27 different professions, providing on-the-job assistance to care provider management and frontline staff.
The company implemented comprehensive security measures including secure development practices, strict access controls, automated monitoring, and employee training. NurseMagic™'s AI technology has demonstrated strong performance, achieving 93% accuracy on NCLEX model questions and 91% accuracy on the USMLE, surpassing the average doctor's pass rate of 76%.